ZEISS announces USFDA clearance of the Quatera 700
The latest technology from ZEISS empowers surgeons with one complete, digitally integrated cataract workflow for efficiency without compromise
The latest technology from ZEISS empowers surgeons with one complete, digitally integrated cataract workflow for efficiency without compromise
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
A comprehensive assessment of the organisational systems for governance, management, operations and consistency in delivered results, this certification is an endorsement of the company's export capabilities and manufacturing prowess
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
BioFluidica LiquidScan harnesses the power of microfluidics
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Subscribe To Our Newsletter & Stay Updated